Verastem shows 45% ORR in LGSOC at ASCO; plans accelerated filing

Verastem, Inc.

Updated RAMP 201 Part A: confirmed ORR 45% in recurrent LGSOC; 86% tumor shrinkage.
FDA Breakthrough Therapy for avutometinib + defactinib; accelerated approval filing planned.
Cash $111M as of Q1 2023; up to $150M credit facility; up to $95M milestones from Secura Bio.
Avutometinib shows best-in-class potential; expanding into NSCLC, pancreatic, CRC trials.
Confirmatory trial for LGSOC initiation expected in H2 2023; multiple readouts in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.